Clinical Trials
This global Phase 3 study is testing whether a targeted treatment called trastuzumab deruxtecan (T-DXd) given after surgery can help people with HER2‑positive endometrial cancer live longer without the cancer returning.
Bizonyítékszint: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.
Kapcsolódó jelek
- Immunotherapy improves endometrial cancer outcomes
- Quality of Life Measures in Advanced Endometrial Cancer: A Systematic Review of Reporting Practices in Phase III Clinical Trials
- Endometrial Cancer - PMC
- Current recommendations and recent progress in endometrial cancer
- Advancements in Endometrial Cancer Research in 2024